Clinical trials: Diabete Type 2
Diabetes Mellitus, Type 2, Endothelial Dysfunction
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes
Type 2 Diabetes Mellitus (T2DM) represents a model of endothelial dysfunction, where chronic nitric oxide deprivation, hyperglycaemia and hyperinsulinemia and fibrogenic mediators lead to cardiovascular remodelling associated…
- Trial name
- CECSID (NCT00692237)
- Testing
- Sildenafil
- Where
- Italy
- Volunteers
- 59 people
- Sponsor
- University of Roma La Sapienza
Type 2 Diabetes, Peripheral Arterial Disease
Liraglutide and Peripheral Artery Disease
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with…
- Trial name
- STARDUST (NCT04881110)
- Testing
- Liraglutide, Control
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Campania Luigi Vanvitelli
Cardiovascular Diseases, Diabetes Type 2
Baseline Oral Health Study: UnCoVer the Connections to General Health
Purpose: The Baseline Oral Health Health Study is a randomized controlled trial to evaluate the impact of regular, professional non-surgical Intensive Periodontal Therapy (scaling and root planing and optimal oral hygiene with…
- Trial name
- NCT04954313
- Testing
- Subgingival chlorhexidine irrigation, Dental Supplies, Periodonal Treatment
- Where
- 2 sites in United States
- Volunteers
- 786 people
- Sponsor
- University of North Carolina, Chapel Hill
Type 2 Diabetes Mellitus
Bexagliflozin Efficacy and Safety Trial
The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events.
- Trial name
- BEST (NCT02558296)
- Testing
- Bexagliflozin
- Where
- 157 sites in United States, Canada and 8 more
- Volunteers
- 1,700 people
- Sponsor
- Theracos
Cardiovascular Risk Factor, Cardiovascular Diseases
Substituting Sitting With Standing and Walking in Free-living Conditions Improves Daily Glucose Profile in South Asians
The purpose of this study is to investigate the effects of substituting sitting under free-living conditions in South Asian adults with overweight and obesity on continuous glucose profiles.
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Diabetes, Type 2 Diabetes
- Trial name
- NCT04645875
- Testing
- SIT regimen, SITless regimen
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Bedfordshire
Prediabetes, Obesity
Effects of Antidiabetic Medications on the Postprandial State in Prediabetes
This project addresses cardiovascular disease risk in patients with prediabetes. Levels of lipids after eating a meal ("postprandial lipids") are strong independent predictors of cardiovascular risk.
- Trial name
- NCT02104739
- Testing
- Exenatide, Saxagliptin, Exenatide extended-release (ER)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate…
- Trial name
- LIRA-SWITCH™ (NCT01907854)
- Testing
- liraglutide, sitagliptin
- Where
- 106 sites in United States, Canada and 5 more
- Volunteers
- 407 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Simplified Insulin Regimen for the Elderly
Basal-bolus insulin therapy, which includes one injection of long acting insulin and three injections of short acting insulin is the most commonly used insulin treatment.
- Trial name
- NCT03660553
- Testing
- Insulin Glargine, Insulin Aspart, Insulin Lispro
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Miami
Diabetes Mellitus, Type 2
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a single-center, Phase 2, randomized, double-blind, 3-way crossover meal study in participants with Type 2 Diabetes Mellitus (T2DM) to determine the optimum dose and compare the pharmacokinetics (PK) and postprandial…
- Trial name
- NCT00916357
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Halozyme Therapeutics
Type 2 Diabetes
Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes
This is an open-label, proof of concept study with a single active treatment arm designed to assess whether CVS-based stimulation has a beneficial effect on patients with type 2 diabetes.
- Trial name
- NCT02130401
- Testing
- TNM Device
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Scion NeuroStim
Type 2 Diabetes Mellitus, Insulin Resistance
Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes
The role of individual leukocyte populations in type 2 diabetes (T2D) and immunometabolism in general represent important gaps in knowledge to better understand the etiopathogenesis of T2D.
- Trial name
- NCT02597101
- Testing
- Metformin, saxagliptin, AZD9668
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nick Giannoukakis, PhD
Diabetes Mellitus, Type 2
Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients
Reduced factorial design study with 24 week randomized treatment of initial combination therapy with linagliptin and metformin in T2DM patients
- Trial name
- NCT01708902
- Testing
- linagliptin2.5mg/metformin1000mg, linagliptin 5mg, Metformin 500mg
- Where
- 56 sites in China, Malaysia and 2 more
- Volunteers
- 876 people
- Sponsor
- Boehringer Ingelheim
Fatty Liver, Nonalcoholic, NAFLD
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Randomized, double-blind, placebo-controlled, parallel-group study comparing multiple doses of HTD1801 to placebo.
- Conditions
- Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Trial name
- NCT03656744
- Testing
- HTD1801
- Where
- 17 sites in United States
- Volunteers
- 101 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
Type 2 Diabetes Mellitus
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
The primary objective is to demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo with respect to hemoglobin A1c (Hb1Ac) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic…
- Trial name
- SOTA-BONE (NCT03386344)
- Testing
- Sotagliflozin
- Where
- 53 sites in United States, Australia and 6 more
- Volunteers
- 376 people
- Sponsor
- Lexicon Pharmaceuticals
Hypogonadism, Peripheral Vascular Disease
Testosterone for Peripheral Vascular Disease
There is increasing evidence of the linkage of type 2 diabetes with low testosterone levels in men.
- Conditions
- Hypogonadism, Peripheral Vascular Disease, Type 2 Diabetes
- Trial name
- NCT00504712
- Testing
- Testosterone, saline
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Barnsley Hospital
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
- Trial name
- PIONEER 3 (NCT02607865)
- Testing
- semaglutide, sitagliptin
- Where
- 242 sites in United States, Argentina and 13 more
- Volunteers
- 1,864 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration
The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or without microalbuminuria with dapagliflozin or metformin for 4 months.
- Trial name
- Hyper (NCT02911792)
- Testing
- Dapagliflozin, Metformin, Glipizide 5 MG
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin.
- Trial name
- NCT05275400
- Testing
- Insulin Efsitora Alfa, Insulin Degludec
- Where
- 127 sites in United States, Argentina and 8 more
- Volunteers
- 986 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)
The purpose of this study is to assess the efficacy of omarigliptin 25 mg weekly (as monotherapy) compared with sitagliptin 50 mg daily and placebo, and the long term safety (up to 52 weeks) of omarigliptin 25 mg weekly.
- Trial name
- NCT01703221
- Testing
- Omarigliptin, Sitagliptin
- Volunteers
- 414 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A First-in-Human Study of LY3009385 in Healthy Participants
The main purpose of this study is to determine the safety of LY3009385 in healthy participants. The study drug is given as a single dose, by injections under the skin. Side effects will be documented.
- Trial name
- NCT01477567
- Testing
- LY3009385
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.